Ari M. Melnick

Director

Josep Carreras Leukaemia Research Institute
Country flagSpain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (29)

Combination therapies offer promise for improving cancer treatment efficacy and preventing recurrence. Preclinical screening strategies can prioritize synergistic drug combinations. However, identifying optimal combinations tailored to specific cancer subtypes and patients is challenging due to the vast number of possibilities and tumor heterogeneity. To address this gap, we developed PAIRWISE which explicitly modeled synergistic effects of drug combinations in cancer cell lines or tumor samples. PAIRWISE outperformed competing models with an AUROC of 0.847 on held-out cancer cell lines. When applied to an independent dataset with Bruton Tyrosine Kinase inhibitors in Diffuse Large B Cell Lymphoma, PAIRWISE accurately predicted synergistic combinations with an AUROC of 0.720. We validated 30 approved or investigational agents for DLBCL treatment and their synergy with BTKi in HTS. PAIRWISE showed strong concordance with in vitro screening results. These findings demonstrate the ability of PAIRWISE to nominate effective personalized drug combinations, accelerating precision oncology development.

Year:

2026

Supplementary Figure S1 shows correlation of EZH2 gene expression with FGA in METABRIC and TCGA breast cancer cohort suggests a link between EZH2 and CIN. Supplementary Figure S2 shows correlation between fraction genome altered (FGA) and EZH2 gene expression in TCGA LUAD cohort. Supplementary Figure S3 shows increased CIN in various TNBC, non-TNBC and and RPE1 cells and impact of EZH2 inhibition. Supplementary Figure S4 shows EZH2 inhibition and cell cycle analysis. Supplementary Figure S5 shows CUT & RUN seq and RNA-seq analysis. Supplementary Figure S6 shows visualization and experimental validation of EZH2 target genes. Supplementary Figure S7 shows EZH2 mediated TNKS regulates CIN. Supplementary Figure S8 shows multipolar mitosis and supernumerary centrosome analysis of the TNKS KO cells. Supplementary Figure S9 shows correlation of EZH2, CPAP and aneuploidy and effect of EZH2 inhibition on CPAP expression and cell cycle analysis of TNKSWT and TNKSKO LM2 cells. Supplementary Figure S10 shows impact of CIN modulation on proliferation and metastatic progression in EZH2 WT and EZH2 KO cells.

Year:

2026

Chromosomal instability (CIN) and epigenetic reprogramming are central drivers of breast cancer progression, yet the mechanisms connecting them remain elusive. Here, we uncover a direct role for EZH2 histone methyltransferase in promoting CIN in triple-negative breast cancer. Across breast cancers, EZH2 expression correlates with copy-number alterations, and its catalytic activity is associated with increased CIN in metastasis-initiating cells. Pharmacologic EZH2 inhibition suppresses CIN, revealing an unexpected vulnerability. Integrated chromatin and transcriptome profiling identified tankyrase (TNKS), a PARP, as a direct transcriptional target of EZH2. Mechanistically, EZH2-mediated TNKS suppression disrupts centrosomal P4.1–associated protein (CPAP), driving centrosome overduplication, multipolar mitosis, and exacerbated CIN. In vivo , CIN suppression is a critical mechanism underlying the antimetastatic effects of EZH2 inhibition. These findings delineate a previously unrecognized epigenetic mechanism governing CIN and establish EZH2 inhibitors as the first therapeutic agents capable of directly suppressing CIN, underscoring the need for trials with metastasis-focused endpoints. Significance: We elucidate epigenetic regulation of CIN through EZH2–TNKS–CPAP-axis and show that CIN suppression is important for the efficacy of EZH2 inhibition on metastasis. These mechanistic insights are informative for developing CIN-suppressing therapies.

Year:

2026

Impaired differentiation is a hallmark of myeloid malignancies 1,2 . Therapies that enable cells to circumvent the differentiation block, such as all- trans retinoic acid (ATRA) and arsenic trioxide (ATO), are by and large curative in acute promyelocytic leukaemia 3 , but whether ‘differentiation therapy’ is a generalizable therapeutic approach for acute myeloid leukaemia (AML) and beyond remains incompletely understood. Here we demonstrate that simultaneous inhibition of the histone demethylase LSD1 (LSD1i) and the WNT pathway antagonist GSK3 kinase 4 (GSK3i) robustly promotes therapeutic differentiation of established AML cell lines and primary human AML cells, as well as reducing tumour burden and significantly extending survival in a patient-derived xenograft mouse model. Mechanistically, this combination promotes differentiation by activating genes in the type I interferon pathway via inducing expression of transcription factors such as IRF7 (LSD1i) and the co-activator β-catenin (GSK3i), and their selective co-occupancy at targets such as STAT1, which is necessary for combination-induced differentiation. Combination treatment also suppresses the canonical, pro-oncogenic WNT pathway and cell cycle genes. Analysis of datasets from patients with AML suggests a correlation between the combination-induced transcription signature and better prognosis, highlighting clinical potential of this strategy. Collectively, this combination strategy rewires transcriptional programs to suppress stemness and to promote differentiation, which may have important therapeutic implications for AML and WNT-driven cancers beyond AML.

Year:

2025

Despite the approval of several new treatments for patients with B-cell lymphoma, there is still a large unmet need. Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the 2 most common B-cell lymphoma subtypes, accounting for ∼50% of all cases. EZH2 heterozygous gain-of-function somatic driver mutations are frequently found in germinal center B-cell DLBCLs and FLs. An EZH2 inhibitor has shown durable responses in patients with relapsed or refractory FL, however a considerable fraction of the patients did not show an objective response. To identify alternative therapeutic strategies, we performed CRISPR/Cas9 knockout screens in B-cell lymphoma cells treated with or without an EZH2 inhibitor. This led to the identification of the histone methyltransferase DOT1L as a potential therapeutic target. Specifically, we showed that an EZH2 inhibitor synergizes with a DOT1L inhibitor in a panel of B-cell lymphoma cell lines regardless of the EZH2 mutation status. Mechanistically, we demonstrated that the 2 inhibitors cooperatively suppress DOT1L-regulated cell cycle genes, upregulate genes involved in interferon signaling, including antigen presenting genes, and ultimately drive B-cell differentiation by derepressing EZH2-regulated plasma cell signature genes. Furthermore, we demonstrated the effectiveness of this epigenetic combination strategy in a xenograft model, which led to significant abrogation of tumor growth. Together, our studies provide preclinical proof-of-concept for an epigenetic combination therapy to overcome resistance and improve durability of response for the treatment of B-cell lymphoma, warranting clinical investigation and illustrating an important convergent role of EZH2 and DOT1L in B-cell lymphomagenesis.

Year:

2025

Hematologic malignancies exhibit disparities in risk and outcomes across populations. A systematic review to identify prospective studies addressing disparities among patients with hematologic malignancies with an intervention or analysis at any level in the “Cells-to-Society” model identified few studies and demonstrated literature gaps, which experts have supplemented with relevant citations. This review presents current research on diagnosis, treatment, and survival disparities and explores the roles of biology, cancer centers, community outreach, patient advocacy, and policies. Emphasis is placed on multilevel collaborative approaches to promote equity in healthcare delivery and improve survival. Significance: This review underscores our shared responsibility to champion multidimensional strategies rooted in basic and translational science, community involvement, and societal responsiveness for a meaningful impact. Unifying themes include the need to enhance collaborative infrastructure to engage laboratory researchers, epidemiologists, data scientists, clinicians, patients, community leaders, and policymakers; patient-level support services; outreach, education, and navigation for patients at the community level; recruitment and retention of underrepresented groups in the healthcare and research workforce; and funding for these efforts.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Diffuse large B cell lymphomas and follicular lymphomas show recurrent mutations in epigenetic regulators; among these are loss-of-function mutations in KMT2D and gain-of-function mutations in EZH2. To systematically explore the effects of these mutations on the wiring of the epigenetic network, we applied a single-cell approach to probe a wide array of histone modifications. We show that mutant-EZH2 elicits extensive effects on the epigenome of lymphomas, beyond alterations to H3K27 methylations, and is epistatic over KMT2D mutations. Utilizing the single-cell data, we present computational methods to measure epigenetic heterogeneity. We identify an unexpected characteristic of mutant-EZH2, but not KMT2D, in increasing heterogeneity, shedding light on a novel oncogenic mechanism mediated by this mutation. Finally, we present tools to reconstruct known interactions within the epigenetic network, as well as reveal potential novel cross talk between various modifications, supported by functional perturbations. Our work highlights novel roles for mutant-EZH2 in lymphomagenesis and establishes new concepts for measuring epigenetic heterogeneity and intra-chromatin connectivity in cancer cells.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Collaborators (42)

Elena I Rugarli

University of Cologne

GERMANY
View details

Cem Meydan

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Yuning Hong

La Trobe University

AUSTRALIA
View details

Ashley Laughney

Associate Professor

Weill Cornell Medicine

UNITED STATES
View details

Olivier Elemento

Professor

Weill Cornell Medical College

UNITED STATES
View details

David W. Scott

The University of British Columbia

CANADA
View details

Nemo Koi Ikonen

University of Helsinki

FINLAND
View details

Gero Knittel

University Hospital Essen

GERMANY
View details

Wendy Cozen

Professor

University of California, Irvine

UNITED STATES
View details

Bethan Psaila

University of Oxford

UNITED KINGDOM
View details

Steven Treon

Professor

Harvard Medical School

UNITED STATES
View details

Wendy Béguelin

Assistant Professor

NYU School of Medicine

UNITED STATES
View details

Dylan McNally

Cornell University

UNITED STATES
View details

Chijioke Nze

Assistant professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Melissa Hubisz

Cornell University

UNITED STATES
View details

Liron Yoffe

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Kristian Helin

CEO, Professor

Institute of Cancer Research

UNITED KINGDOM
View details

Leandro Cerchietti

Professor

NYU Langone Health

UNITED STATES
View details

Jude Fitzgibbon

Professor in Personalised Cancer Medicine

Queen Mary University of London

UNITED KINGDOM
View details

Michelle Hildebrandt

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Darko Barisic

Assistant Professor

Weill Cornell Medicine

UNITED STATES
View details

Shirong Liu

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Johana L Gutierrez

NewYork-Presbyterian Hospital/Weill Cornell Medical Center

UNITED STATES
View details

Cihangir Duy

Assistant Professor

Fox Chase Cancer Center

UNITED STATES
View details

Alan Melcher

Professor of Translational Immunotherapy

Institute of Cancer Research

UNITED KINGDOM
View details

Sylvain Nguyen

University of Oxford

UNITED KINGDOM
View details

Rulla Tamimi

Professor

Weill Cornell Medicine

UNITED STATES
View details

Graziella Bosco

University of Cologne

GERMANY
View details

Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Dinis Calado

Senior Group Leader

Babraham Institute

UNITED KINGDOM
View details

Reinhard Büttner

Head of Department

University of Cologne

GERMANY
View details

Philipp Sergeev

University of Helsinki

FINLAND
View details

Bjoern Chapuy

Professoor

Charité - Universitätsmedizin Berlin

GERMANY
View details

Thuy Mai Van Nguyen

Imperial College London

UNITED KINGDOM
View details

qiang pan-hammarstrom

Professor, head of the Immunology Division

Karolinska University Hospital

SWEDEN
View details

Bastian von Tresckow

University of Cologne

GERMANY
View details

Jerome Fortin

Assistant Professor

McGill University

CANADA
View details

Henry Withers

Research Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jorge Castillo

Clinical Director, Bing Center for Waldenstrom Macroglobulinemia

Dana-Farber Cancer Institute

UNITED STATES
View details

vivek mittal

Professor/Director

Weill Cornell Medicine

UNITED STATES
View details

Hans Christian Reinhardt

-

GERMANY
View details

Christopher Mason

Professor

Weill Cornell Medical College

UNITED STATES
View details